
Multisite 3 BRACAnalysis® Three Mutation BRCA1 and BRCA2 Analysis for Ashkenazi Individuals





Meigning le Ne

SPECIMEN

Specimen Type: Blood

Draw Date: Accession Date: Jul 23, 2009 Jul 24, 2009

Report Date:


Jul 31, 2009

Name: Date of Birth:

Patient ID: Gender:

Accession #:

Requisition #:



Test Results and Interpretation

NO MUTATION DETECTED

Test Performed Result Interpretation 187delAG BRCA1 No Mutation Detected No Mutation Detected 5385insC BRCA1 No Mutation Detected No Mutation Detected 6174delT BRCA2 No Mutation Detected No Mutation Detected

Analysis consists of the specific mutations indicated above. The BRCA1 mutations 187delAG and 5385insC are also known as 185delAG and 5382insC respectively.

This test is designed to detect the mutations 187delAG and 5385insC within BRCA1 and 6174delT within BRCA2. This test result does not exclude the possibility of other predisposing mutations that have been reported in individuals of Ashkenazi ancestry (Robson ME et. al., Lancet 350:117-118, 1997; Schubert EL et. al., Am J Human Genetics 60:1031-1040, 1997). Considerations for additional testing:

1) If this individual has never had breast or ovarian cancer and no mutation has been identified previously in the family, it is recommended that testing an affected relative be considered to help clarify the clinical significance of this individual's negative test result. If the affected family member is found to have a mutation not identified by Multisite 3 BRACAnalysis, it is recommended that this patient be tested for that specific mutation.

2) If a specific BRCA1 or BRCA2 mutation has not been identified in a family member, and there is a sufficiently high probability of a mutation in this individual based upon personal or family history of cancer, comprehensive BRACAnalysis may be warranted for this individual.

AUG 1 0 2009

Subject 6 ACA results

Please contact Myriad Professional Support at 1-800-469-7423 to discuss any questions regarding this result.

Benjamin B. Roa, Ph.D.

Diplomate ABMG Laboratory Director

Richard J. Wenstrup, MD Diplomate ABMG Chief Medical Officer

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. It is strongly recommended that these results be communicated to the patient in a setting that includes appropriate counseling. The accompanying Technical Specifications summary describes the analysis, method, performance characteristics, nomenclature, and interpretive criteria of this test. This test may be considered investigational by some states. This test was developed and its performance characteristics determined by Myriad Genetic Laboratories. It has not been reviewed by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.